Last updated: August 10, 2026
Comirnaty, Pfizer and BioNTech's mRNA COVID-19 vaccine, generated approximately $91.2 billion in cumulative Pfizer revenue from 2021 through 2024. Revenue peaked at $37.8 billion in 2022 before falling to $11.2 billion in 2023 and approximately $5.4 billion in 2024 as government purchasing ended, vaccination shifted to seasonal demand, and competing products entered the commercial market.[1-4] The product remains commercially relevant, but its financial profile has changed from pandemic-scale sales to a recurring respiratory-vaccine franchise.
How much revenue has Comirnaty generated?
Pfizer reported the following Comirnaty revenue:
| Fiscal year |
Comirnaty revenue |
Year-over-year change |
Primary market condition |
| 2021 |
$36.8 billion |
Not comparable |
Initial global rollout and government procurement |
| 2022 |
$37.8 billion |
2.8% increase |
Large government contracts and booster demand |
| 2023 |
$11.2 billion |
70.3% decline |
Commercial transition and excess inventory |
| 2024 |
Approximately $5.4 billion |
Approximately 52% decline |
Seasonal demand and lower vaccination rates |
Sources: Pfizer annual reports and fourth-quarter earnings disclosures.[1-4]
Comirnaty was Pfizer's largest product in 2021 and 2022. Its 2022 revenue exceeded the annual sales of most established pharmaceutical franchises. The subsequent decline reflects market normalization rather than product withdrawal or loss of regulatory approval.
Pfizer does not disclose Comirnaty operating profit. Product-level margin analysis is therefore unavailable. Gross profitability declined as production volumes fell, fixed manufacturing capacity was underutilized, and Pfizer recorded charges related to excess COVID-19 inventory and manufacturing commitments.[3]
Why did Comirnaty revenue decline after 2022?
The main drivers were structural:
- Government procurement contracts expired or were reduced.
- Vaccination shifted from mass campaigns to seasonal vaccination.
- Many individuals delayed or declined additional doses after prior vaccination or infection.
- U.S. distribution moved into a commercial channel with private insurers, pharmacies, providers, and government programs.
- Moderna's Spikevax and Novavax's protein-based vaccine increased competition.
- Pfizer reduced production in response to lower demand, but inventory and supply-chain charges affected results.
The commercial transition changed the revenue model. During the pandemic, Pfizer sold large volumes under advance-purchase agreements. In the commercial market, manufacturers must manage wholesaler inventory, payer coverage, pharmacy ordering, seasonal demand, and lower utilization.
The commercial channel also allows higher contractual prices per dose than many government contracts. That price benefit has not offset the sharp reduction in doses administered.
What is the market outlook for Comirnaty?
Comirnaty's market is now a recurring seasonal vaccine market rather than a mass-immunization market. The core demand base consists of older adults, immunocompromised individuals, people with chronic conditions, healthcare workers, and consumers seeking updated protection.
The U.S. market remains strategically important because it has:
- A large adult population eligible for updated vaccination.
- Annual or periodic reformulation requirements.
- Public-sector coverage for uninsured and underinsured populations.
- Established pharmacy distribution.
- Strong brand recognition.
Demand is sensitive to the timing of updated strain recommendations. If regulatory recommendations arrive late or consumers postpone vaccination until a later respiratory-virus season, manufacturers can experience inventory mismatches.
Pfizer's principal commercial competitors are Moderna's Spikevax and Novavax's Nuvaxovid. Sanofi and Novavax also participate in broader COVID-19 vaccine development and supply arrangements, but mRNA vaccines remain the dominant technology in the U.S. COVID-19 commercial market.
How does Comirnaty compare with Spikevax and Nuvaxovid?
| Product |
Manufacturer |
Technology |
Commercial position |
Key competitive factor |
| Comirnaty |
Pfizer/BioNTech |
Modified mRNA in lipid nanoparticles |
Largest historical COVID-19 vaccine franchise |
Global scale, pharmacy access, brand recognition |
| Spikevax |
Moderna |
Modified mRNA in lipid nanoparticles |
Primary direct competitor |
Focused respiratory-vaccine portfolio |
| Nuvaxovid |
Novavax |
Recombinant protein with adjuvant |
Smaller, non-mRNA alternative |
Appeal to individuals seeking non-mRNA technology |
Comirnaty and Spikevax compete most directly because both use updated mRNA formulations and rely on seasonal vaccination. Their differentiation is based less on mechanism than on supply reliability, distribution, physician and pharmacy relationships, safety perception, government recommendations, and payer access.
Novavax can capture demand from consumers who prefer a protein-based vaccine. Its smaller manufacturing and commercial infrastructure limits its ability to displace the two major mRNA products at scale.
What is the FDA regulatory status of Comirnaty?
Comirnaty received full FDA approval on August 23, 2021, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 12 years and older at the time of original approval.[5] The FDA subsequently authorized and approved updated formulations for younger age groups and seasonal variants.
The product is regulated as a biologic under a biologics license application, or BLA. Updated formulations have been handled through supplements, amendments, and regulatory updates rather than through a new standalone vaccine product for every strain.
The FDA's regulatory framework permits periodic updates to COVID-19 vaccines as circulating strains change. The commercial consequence is that Comirnaty must remain operationally flexible: Pfizer must update the sequence, manufacture at scale, obtain regulatory clearance, and distribute the new formulation within a narrow seasonal window.
What is the Orange Book status of Comirnaty?
Comirnaty is not protected through the conventional small-molecule Orange Book framework. The FDA's Orange Book primarily identifies patents and exclusivity for approved drug products, while licensed biologics are tracked through the Purple Book and biologics-related FDA records.[6]
For Comirnaty, the relevant regulatory protections include:
- BLA approval.
- Biologic reference-product exclusivity.
- Patent rights held by Pfizer, BioNTech, and potentially third parties.
- Trade secrets and manufacturing know-how.
- Regulatory and manufacturing barriers associated with updated mRNA vaccines.
The absence of a conventional Orange Book listing does not mean that Comirnaty lacks patent protection. It means that biosimilar and interchangeable-biologic competition is assessed through the BPCIA framework rather than the abbreviated new drug application and Paragraph IV framework used for small-molecule generics.
When does Comirnaty lose biologic exclusivity?
The BPCIA provides 12 years of reference-product exclusivity for a licensed biologic in the United States. Because Comirnaty received its original BLA approval on August 23, 2021, the baseline statutory exclusivity period runs to approximately August 2033, subject to the precise regulatory calculation and any applicable pediatric exclusivity.[5,7]
This date is separate from patent expiration. A biosimilar sponsor may attempt to begin the BPCIA patent-exchange process before exclusivity ends, but FDA approval and commercial launch cannot occur before the applicable exclusivity period expires.
The 2033 date is therefore the principal U.S. biosimilar timing marker. Patent litigation could delay or constrain a launch beyond that point, while patent expiry could create commercial freedom only if regulatory exclusivity and other barriers have also expired.
Are there Paragraph IV challenges to Comirnaty?
A conventional Paragraph IV challenge is not the principal pathway for Comirnaty because it is a biologic, not a conventional small-molecule drug. Biosimilar applicants use the BPCIA patent-disclosure and patent-litigation process rather than filing an ANDA with Paragraph IV certifications.
The practical implication is that market participants should monitor:
- Purple Book listings.
- Biosimilar applications and FDA approvals.
- Patent-disclosure notices.
- Declaratory-judgment actions.
- Federal patent litigation.
- Settlement agreements between reference-product sponsors and biosimilar applicants.
As of the relevant public reporting period, Comirnaty did not face an established U.S. biosimilar launch comparable to the generic-entry wave affecting small-molecule products. The earliest realistic U.S. biosimilar pressure is linked to the 2033 reference-product exclusivity endpoint, although a biosimilar could receive approval only after satisfying FDA requirements and resolving applicable patent issues.
What patents protect Comirnaty?
Comirnaty's protection is distributed across several technology layers:
| Protection layer |
Subject matter |
Commercial relevance |
| mRNA sequence and construct |
Vaccine RNA sequence, codon optimization, untranslated regions, and expression elements |
May cover specific vaccine designs |
| Lipid nanoparticles |
Ionizable lipids, helper lipids, cholesterol, PEG-lipids, and particle composition |
Protects delivery technology |
| Formulation |
Buffer systems, cryoprotectants, concentration, and storage conditions |
Supports stability and distribution |
| Manufacturing |
RNA synthesis, purification, encapsulation, filling, and quality control |
Creates operational barriers |
| Method of use |
Prevention of COVID-19 and vaccination schedules |
May provide narrower claim coverage |
| Regulatory exclusivity |
BLA-based biologic exclusivity |
Blocks earlier biosimilar approval |
Public patent records contain numerous patents and applications associated with Pfizer, BioNTech, their licensors, and third-party platform providers. A single expiration date does not describe the Comirnaty estate. Patent terms vary by filing date, patent-family priority, terminal disclaimers, patent-term adjustment, patent-term extension, claim scope, and jurisdiction.
Key commercial risks arise from third-party mRNA and lipid-nanoparticle patents. Moderna has pursued patent litigation against Pfizer and BioNTech in multiple jurisdictions concerning COVID-19 vaccine technology. Other companies, including Alnylam Pharmaceuticals and Arbutus Biopharma, have asserted lipid-nanoparticle-related rights in disputes involving mRNA vaccines. These cases can produce royalty exposure, damages claims, licensing obligations, claim invalidation, or restrictions on specific manufacturing practices.[8-10]
What patent litigation affects Comirnaty?
The most important litigation categories are:
Moderna versus Pfizer and BioNTech
Moderna filed patent-infringement claims concerning mRNA vaccine technology in the United States and other jurisdictions. The disputes concern patents related to mRNA vaccine architecture and delivery technology. Their commercial significance is potential royalty liability or restrictions on future sales, although the outcome depends on the validity and scope of individual claims in each jurisdiction.[8]
Lipid-nanoparticle disputes
Lipid nanoparticles are central to Comirnaty's delivery system. Patent disputes involving ionizable lipids and nanoparticle formulations may affect the product even when the asserted patents do not claim the vaccine's mRNA sequence.
Licensing and royalty exposure
Pfizer and BioNTech have entered into arrangements with technology licensors and research institutions. BioNTech's relationship with the University of Pennsylvania and other technology contributors has generated royalty obligations associated with foundational mRNA technology. Pfizer and BioNTech also operate under a collaboration structure that allocates economics between the parties.[11]
No single publicly available patent schedule establishes a definitive worldwide "last patent expiry" for Comirnaty. The relevant analysis must be conducted by jurisdiction, claim family, formulation, manufacturing step, and litigation outcome.
Does Comirnaty face biosimilar risk?
Biosimilar risk is low in the near term and increases materially after 2033 in the United States. The product's barriers include:
- Complex mRNA characterization.
- Lipid-nanoparticle manufacturing.
- Product-specific analytical requirements.
- Strain-update requirements.
- Cold-chain and stability controls.
- Large-scale sterile manufacturing.
- Patent and licensing disputes.
- Limited commercial visibility into seasonal demand.
A biosimilar or follow-on product would need to demonstrate high similarity to a reference product whose antigenic sequence may change over time. This creates a more complex development and regulatory problem than copying a stable small-molecule active ingredient.
The most likely early competition is not a traditional generic launch. It is competition from alternative updated vaccines, new delivery systems, combination respiratory vaccines, and potentially region-specific follow-on biologics.
How does the Pfizer-BioNTech licensing structure affect Comirnaty economics?
Pfizer and BioNTech jointly commercialize Comirnaty in most markets outside certain territories covered by separate arrangements. The companies have disclosed a profit-sharing structure under which economics are generally divided between Pfizer and BioNTech, after specified costs and contractual obligations.[11]
The arrangement gives Pfizer global commercial and manufacturing scale while giving BioNTech an economic interest in sales and access to Pfizer's distribution infrastructure. BioNTech's revenue concentration is materially higher because Comirnaty remains its dominant commercial product.
China is a separate strategic market. Fosun Pharma has been associated with BioNTech's commercialization and distribution arrangements for the vaccine in China, creating a different geographic and contractual structure from the Pfizer-led commercial model.[12]
What generic or biosimilar launch scenarios exist for Comirnaty?
Base case: seasonal brand persistence
Pfizer and BioNTech retain meaningful share through 2030, supported by brand awareness, manufacturing scale, pharmacy access, and annual formulation updates. Revenue continues to decline from pandemic levels but stabilizes as a recurring seasonal product.
Downside case: accelerated price and volume erosion
More consumers decline vaccination, payers exert price pressure, and competitors capture high-risk and vaccine-hesitant populations. Revenue falls below a stable seasonal base, while manufacturing and inventory costs reduce margins.
Long-term entry case: biosimilar or follow-on competition after 2033
A follow-on biologic enters after regulatory exclusivity ends, subject to patent clearance and FDA approval. Initial erosion may be slower than for small-molecule generics because of manufacturing complexity and the absence of automatic substitution in many settings.
Technology-displacement case
A combination respiratory vaccine, improved protein vaccine, longer-lasting vaccine, or different delivery platform reduces demand for standalone Comirnaty. This is a product-technology risk rather than a patent-expiry event.
How much revenue exposure does Pfizer have to Comirnaty?
Comirnaty represented approximately:
| Fiscal year |
Comirnaty share of Pfizer total revenue |
| 2021 |
Approximately 45% |
| 2022 |
Approximately 45% |
| 2023 |
Approximately 22% |
| 2024 |
Approximately 11% |
The percentage declined because Comirnaty revenue fell while Pfizer's total revenue also changed after the pandemic portfolio normalized. The product is no longer the central determinant of Pfizer's consolidated earnings, but it remains a significant contributor to BioNTech and a material seasonal asset for Pfizer.
Pfizer's future COVID-19 revenue depends on dose volume, commercial price, product updates, international demand, government purchases, and the company's ability to align production with seasonal uptake.
Key Takeaways
- Comirnaty generated approximately $91.2 billion in Pfizer revenue from 2021 through 2024.
- Revenue peaked at $37.8 billion in 2022 and declined to approximately $5.4 billion in 2024.
- The decline reflects market normalization, not withdrawal of FDA approval.
- U.S. demand is now seasonal and concentrated in older, immunocompromised, and higher-risk populations.
- Spikevax is the principal direct competitor; Nuvaxovid provides a non-mRNA alternative.
- Comirnaty is governed by biologic regulation and is not subject to a conventional Orange Book Paragraph IV pathway.
- The baseline U.S. biologic exclusivity endpoint is approximately August 2033.
- Patent risk includes mRNA, lipid-nanoparticle, formulation, manufacturing, and third-party licensing claims.
- Pfizer's principal financial risk is continued volume erosion and price pressure, while BioNTech has greater exposure because of its higher revenue concentration.
- The most probable competitive path before 2033 is seasonal branded competition, not traditional generic substitution.
FAQs
Is Comirnaty still commercially available?
Yes. FDA-approved Comirnaty formulations remain available in the United States, with periodic updates addressing circulating SARS-CoV-2 variants.[5]
Is Comirnaty a biologic or a drug?
Comirnaty is a biologic vaccine licensed under a BLA. It is not regulated as a conventional small-molecule drug approved through an NDA.
Can a generic company copy Comirnaty?
A conventional generic cannot use the standard ANDA pathway to copy Comirnaty. A competitor would generally need to pursue a biosimilar or other biologic pathway and address patent, manufacturing, and regulatory requirements.
Who owns Comirnaty?
Comirnaty is commercialized through a Pfizer-BioNTech collaboration. Pfizer is the major commercial and manufacturing partner in many markets, while BioNTech retains substantial economic and technology rights under the collaboration agreements.[11]
What is the largest future threat to Comirnaty sales?
The largest near-term threat is lower seasonal vaccination uptake combined with competition from updated mRNA and non-mRNA vaccines. The longer-term threat is a combination of biosimilar entry, patent disputes, and improved vaccine technologies.
References
- Pfizer Inc. (2022). 2021 annual report.
- Pfizer Inc. (2023). 2022 annual report.
- Pfizer Inc. (2024). 2023 annual report.
- Pfizer Inc. (2025). 2024 annual report.
- U.S. Food and Drug Administration. (2021-2024). Comirnaty and COVID-19 vaccine regulatory actions.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. ยง 262.
- Moderna, Inc. (2022). Moderna files patent infringement lawsuits against Pfizer and BioNTech.
- Alnylam Pharmaceuticals, Inc. (2022). Patent litigation involving COVID-19 vaccine delivery technology.
- Arbutus Biopharma Corporation. (2022-2024). Intellectual property litigation disclosures.
- BioNTech SE. (2024). Annual report and Pfizer collaboration disclosures.
- Fosun Pharma. (2024). Annual report and BioNTech vaccine commercialization disclosures.
